Rock Springs Capital Management LP Increased Rigel Pharmaceuticals (RIGL) Holding; Roche Holding AG (RHHBY) Covered By 3 Bulls

April 17, 2018 - By Vivian Currie

Roche Holding AG (OTCMKTS:RHHBY) Logo

Among 5 analysts covering Roche Hldg (OTCMKTS:RHHBY), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Roche Hldg had 9 analyst reports since December 2, 2015 according to SRatingsIntel. The company was downgraded on Wednesday, October 18 by Citigroup. Piper Jaffray initiated Roche Holding AG (OTCMKTS:RHHBY) on Friday, January 22 with “Overweight” rating. The firm has “Hold” rating given on Tuesday, October 24 by Berenberg. On Wednesday, December 2 the stock rating was upgraded by Citigroup to “Buy”. Cowen & Co maintained the shares of RHHBY in report on Thursday, October 19 with “Buy” rating. As per Monday, July 10, the company rating was maintained by Cowen & Co. The rating was maintained by Cowen & Co with “Buy” on Monday, September 18. The stock of Roche Holding AG (OTCMKTS:RHHBY) has “Buy” rating given on Monday, August 14 by Cowen & Co. See Roche Holding AG (OTCMKTS:RHHBY) latest ratings:

24/10/2017 Broker: Berenberg Rating: Hold Downgrade
19/10/2017 Broker: Cowen & Co Rating: Buy New Target: $38.0 Maintain
18/10/2017 Broker: Citigroup Rating: Hold Downgrade

Rock Springs Capital Management Lp increased Rigel Pharmaceuticals Inc (RIGL) stake by 147.5% reported in 2017Q4 SEC filing. Rock Springs Capital Management Lp acquired 1.48 million shares as Rigel Pharmaceuticals Inc (RIGL)’s stock rose 8.02%. The Rock Springs Capital Management Lp holds 2.48 million shares with $9.60M value, up from 1.00 million last quarter. Rigel Pharmaceuticals Inc now has $543.06 million valuation. The stock decreased 1.21% or $0.045 during the last trading session, reaching $3.685. About 1.50 million shares traded or 1.16% up from the average. Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) has risen 9.91% since April 17, 2017 and is uptrending. It has underperformed by 1.64% the S&P500.

Investors sentiment increased to 2.06 in Q4 2017. Its up 0.67, from 1.39 in 2017Q3. It increased, as 14 investors sold RIGL shares while 18 reduced holdings. 22 funds opened positions while 44 raised stakes. 127.13 million shares or 21.87% more from 104.32 million shares in 2017Q3 were reported. Ameritas Prtn Inc holds 0% or 10,390 shares in its portfolio. Sg Americas Securities Llc invested in 0% or 14,283 shares. State Board Of Administration Of Florida Retirement reported 0% in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL). Vanguard Grp Inc accumulated 6.22 million shares or 0% of the stock. Deutsche Commercial Bank Ag reported 0% stake. State Street has invested 0% in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL). Teacher Retirement Systems Of Texas stated it has 46,680 shares or 0% of all its holdings. Axa invested in 0% or 33,400 shares. Alliancebernstein LP holds 0% or 503,040 shares. Blackrock stated it has 0% of its portfolio in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL). Wealthtrust invested in 1,210 shares. D E Shaw & Co invested 0.01% in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL). Nea Mngmt Com Ltd Limited Liability Company reported 3.24M shares. Teachers Retirement Systems Of The State Of Kentucky owns 70,200 shares for 0% of their portfolio. Pura Vida Invests Ltd Llc holds 604,563 shares.

Rock Springs Capital Management Lp decreased Anaptysbio Inc stake by 7,600 shares to 142,400 valued at $14.34 million in 2017Q4. It also reduced Galapagos Nv stake by 29,000 shares and now owns 185,000 shares. Aclaris Therapeutics Inc was reduced too.

Among 6 analysts covering Rigel Pharmaceuticals (NASDAQ:RIGL), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Rigel Pharmaceuticals had 23 analyst reports since August 8, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Wednesday, March 7 by H.C. Wainwright. Zacks upgraded Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) on Saturday, August 8 to “Hold” rating. The stock of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) has “Overweight” rating given on Tuesday, August 30 by Piper Jaffray. H.C. Wainwright maintained Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) rating on Friday, January 19. H.C. Wainwright has “Buy” rating and $7.0 target. The firm has “Overweight” rating given on Monday, June 13 by Piper Jaffray. The stock of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) earned “Buy” rating by Jefferies on Monday, May 16. Jefferies maintained Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) on Monday, September 4 with “Buy” rating. H.C. Wainwright maintained the shares of RIGL in report on Friday, February 2 with “Buy” rating. The firm has “Buy” rating given on Tuesday, April 3 by H.C. Wainwright. The firm has “Buy” rating given on Wednesday, April 4 by Jefferies.

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: